T1	Participants 381 465	recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
T2	Participants 467 529	whose disease has progressed after platinum-containing therapy
T3	Participants 978 1089	121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 respectively).
